IMNN — Imunon, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 749647 ·
Last close
$0.61
Market Cap
$3.97M
52W High
$4.35
52W Low
$0.50
ADV30
187,418
Next earnings
—
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma. It is also developing IMNN-101, a COVID-19 booster vaccine that has completed a Phase 1 clinical trial. In addition, the company develops non-viral DNA technology across modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; and PlaCCine for the coding of viral antigens that can elicit a strong immunological response. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was incorporated in 1982 and is headquartered in Lawrenceville, New Jersey.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -3,447,701 -3,750,287 12,008,678 4,039,298 9,386,352
Jun 2026 — — — — — — —
Mar 2026 0 — -4,306,552 -4,249,022 8,018,713 4,794,070 4,659,082
Dec 2025 0 — -4,261,703 -4,222,850 12,288,116 8,781,059 5,226,240

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-13,870,802
Investing CF
$-74,461
Financing CF
$17,773,100
CapEx
$-282,364
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-3.18
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-432,111,495
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-14,791,250
Pretax Income TTM
$-15,036,273
Interest Exp TTM
$341,406
Analysts
5

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -14,650,694 -14,495,028 12,288,116 5,226,240 7,061,876 -13,896,624
Dec 2024 0 -19,132,446 -18,620,242 9,717,364 5,473,066 4,244,298 -18,854,970
Dec 2023 0 -21,030,430 -19,514,977 21,918,069 8,530,427 13,387,642 -19,022,148
Dec 2022 500,000 -24,921,565 -35,898,234 43,975,894 14,648,028 29,327,866 -23,096,895

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-14,715,110
OpCashFlow TTM
—
Assets (Latest)
$14,989,113
Forward EPS
$-1.68

Peers — same industry

TickerNameMarket CapLastDaily %
XTLB XTL BIOPHARMACEUTICALS LTD $3.98M $1.62 —
SILO Silo Pharma, Inc. $4.00M $1.71 —
RVPH REVIVA PHARMACEUTICALS HOLDINGS, INC. $4.02M $0.31 —
KPRX KIORA PHARMACEUTICALS INC $4.11M $0.93 —
SXTC China SXT Pharmaceuticals, Inc. $3.78M $2.86 —

News headlines (Yahoo Finance, 1h cache)

Imunon, Inc. Q3 2026 Earnings Call Summary
2026-11-13 01:44 · Yahoo
Imunon (IMNN) Q3 2026 Earnings Call Transcript
2026-11-12 23:00 · Yahoo
IMUNON Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-12 13:00 · Yahoo
IMUNON Presents New Translational Data at SITC 2026 Demonstrating How IMNN-001 Activates and Sustains Anti-Tumor T-Cell Immunity in Advanced Ovarian Cancer
2026-11-06 14:00 · Yahoo
IMUNON to Hold Third Quarter 2026 Financial Results and Business Update Conference Call on Thursday, November 12, 2026
2026-11-02 13:30 · Yahoo
IMUNON Announces Strategic Sale of ThermoDox®
2026-10-21 12:15 · Yahoo
IMUNON to Participate in Upcoming Investor Conferences
2026-10-08 13:00 · Yahoo
IMNN: R&D Day Highlights IMNN-001 Data in Frontline Ovarian Cancer
2026-10-01 15:40 · Yahoo
IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan
2026-09-24 12:05 · Yahoo
IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review
2026-09-22 12:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.